Status:
COMPLETED
Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)
Lead Sponsor:
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons, with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS and remains the m...
Eligibility Criteria
Inclusion
- Amyotrophic lateral sclerosis :definite, probable or probable with EMG (Airlie House Criteria, 1998).
- Forced vital capacity \>70% pred.
- Daytime PaCO2 \<43 mmHg.
- Venous HCO3- \<28 mmol/L
Exclusion
- Patients unable to perform pulmonary function tests or nocturnal recordings.
- Coexisting significant lung disease: moderate to severe asthma or COPD
- Current NIV, CPAP or oxygen therapy.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00879593
Start Date
April 1 2009
End Date
January 1 2017
Last Update
January 26 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
PEREZ
Lille, France, 59037
2
Pôle des maladies respiratoires et service EFR- Centre hospitalier Regional Universitaire
Lille, France